Patients with SARS-CoV2 treated for pneumonia with Toculizumab had a marked decrease in the inflammatory markers such as CRP and ferritin, along with significant clinical improvement post-infusion (118). The gene discussed is CRP; the disease is susceptibility to pneumonia measurement.